RESEARCHERS at the University of Notre Dame are recruiting people to take part in a ground-breaking study on the use of medicinal cannabis to treat dementia.
The world-leading clinical trial, aimed at improving the quality of life for thousands of people with dementia, will be undertaken by the university’s Institute for Health Research in partnership with Israel-based company MGC Pharmaceuticals.
The 14-month clinical trial will involve 50 people aged 65 and older who have mild dementia and live in an aged-care facility.
The trial will use medicinal cannabis in the form of a mouth spray containing cannabidiol ingredients that have been found to help with nausea, mild anxiety and provide anti-inflammatory benefits.
Chief investigator Amanda Timler said medicinal cannabis “works well with a lot behavioural and neuro-psychotic symptoms associated with dementia, such as aggression and agitation”.
“Medicinal cannabis is also thought to increase appetite as well as improve sleep cycles,” she said.
More than 447,000 Australians live with dementia and more than 1.5 million Australians are involved in their care.
Treatments for behavioural and psychiatric symptoms of dementia are limited and there have been no new treatments for about 15 years.
IHR director Jim Codde said the aim of the study was to improve the quality of life for people with dementia and Alzheimer’s.
Aged care facility managers who are interested in having suitable residents involved can contact Dr Timler on 9433 0795 or via email at Amanda.Timler@nd.edu.au.
Originally published here: https://thewest.com.au/lifestyle/medicine/university-of-notre-dame-goes-green-on-cannabis-trial-for-dementia-patients-ng-b881160541z